Manufacturer or GPO Program year 2021 Source: CMS Open Payments

Boehringer Ingelheim Mexico SA de CV

Mexico

CMS manufacturer 100000010495

Open in the dashboard

General payments

$81,559

51 payments

Research payments

$0

0 payments

Ownership & investment interest

$0

None reported

Through program year 2021, Boehringer Ingelheim Mexico SA de CV reported paying $81,559 in general payments and $0 in research payments to U.S. physicians, teaching hospitals and other recipients.

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

3 rows
Year Kind Amount Payments
2021 General $41,950 16
2020 General $35,859 34
2019 General $3,750 1

Breakdown

Top recipients General payments · program year 2021
  1. Darren McGuire Cardiovascular Disease · Dallas, TX $8,000 2 payments
  2. Javed Butler Advanced Heart Failure and Transplant Cardiology · Jackson, MS $6,400 2 payments
  3. Antonio Anzueto Pulmonary Disease · San Antonio, TX $5,300 4 payments
  4. Julio Rosenstock Endocrinology, Diabetes & Metabolism · Dallas, TX $4,000 1 payment
  5. Rodolfo Galindo Endocrinology, Diabetes & Metabolism · Miami, FL $4,000 2 payments
  6. Maria Rosa Costanzo Advanced Heart Failure and Transplant Cardiology · Naperville, IL $3,600 1 payment
  7. Kristin Highland Pulmonary Disease · Cleveland, OH $3,150 1 payment
  8. Donald Mahler Pulmonary Disease · Lebanon, NH $3,000 1 payment
  9. Kevin Brown Pulmonary Disease · Denver, CO $2,500 1 payment
  10. Janet McGill Endocrinology, Diabetes & Metabolism · Saint Louis, MO $2,000 1 payment
Products the payments named General payments · program year 2021
  1. Jardiance Diabetes $20,000 45% · 4 recipients
  2. Stiolto Respimat Respiratory $8,300 19% · 2 recipients
  3. Tradjenta Diabetes $8,000 18% · 3 recipients
  4. Ofev Respiratory $5,650 13% · 2 recipients
  5. Combivent Respimat Respiratory $2,600 6% · 1 recipient

Each share is of this company’s general payments naming a product in 2021. A payment can name up to five products, so these amounts overlap.

Specialties paid General payments · program year 2021
  1. Pulmonary Disease Internal Medicine $13,950 33% · 4 practitioners
  2. Advanced Heart Failure and Transplant Cardiology Internal Medicine $10,000 24% · 2 practitioners
  3. Endocrinology, Diabetes & Metabolism Internal Medicine $10,000 24% · 3 practitioners
  4. Cardiovascular Disease Internal Medicine $8,000 19% · 1 practitioner

Each share is of this company’s general payments to practitioners with a specialty in 2021. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2021
  1. Texas $17,300 41% · 3 recipients
  2. Mississippi $6,400 15% · 1 recipient
  3. New York $4,000 10% · 1 recipient
  4. Illinois $3,600 9% · 1 recipient
  5. Ohio $3,150 8% · 1 recipient

The top 5 of 8 states; each share is of this company’s general payments in 2021 where a state was reported.

The top 25 states, free in the app

What the payments were for General payments · program years 2019–2021
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $70,200 27 payments
  2. Consulting Fee $7,576 5 payments
  3. Travel and Lodging $3,657 13 payments
  4. Food and Beverage $125 6 payments
Companies with a similar name General payments · program years 2019–2021
  1. Boehringer Ingelheim Pharmaceuticals, Inc. CT, United States $119,273,072
  2. Boehringer Ingelheim International GmbH Germany $23,700,916
  3. Boehringer Ingelheim RCV GmbH & Co KG Austria $1,008,478
  4. Boehringer Ingelheim Pharma GmbH & Co.KG Germany $565,806
  5. Boehringer Ingelheim MENA (Scientific Office) FZ-LLC United Arab Emirates $190,403
  6. Boehringer Ingelheim (Phil.) Inc. Philippines $156,755
  7. Boehringer Ingelheim Singapore Pte. Ltd. Singapore $135,030
  8. Boehringer Ingelheim b.v. Netherlands $129,191
  9. Boehringer Ingelheim Do Brasil Quimica e Farmaceutical Ltda. Brazil $112,993
  10. Boehringer Ingelheim Pty Ltd Australia $91,255

Grouped by name only. CMS publishes no corporate ownership, so a shared name does not mean a shared parent. The largest 10 of 34.

51 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers of drugs, devices and biologicals, and group purchasing organisations, are required to report the payments and transfers of value they make to physicians and teaching hospitals. This page shows what this company reported.

Provenance

Source: CMS Open Payments · through program year 2021

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record